XERS Q2 2018 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$982M

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$819,000+45.0% YoY

Gross Profit

$819,000100.0% margin

Operating Income

-$12M-1508.8% margin

Net Income

-$13M-1585.7% margin

EPS (Diluted)

$-3.07

QoQ Revenue Growth

+211.4%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$361,000

Balance Sheet

Total Assets

$138M

Total Liabilities

$29M

Stockholders' Equity

$109M

Cash & Equivalents

$135M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$819,000	$565,000	+45.0%
Gross Profit	$819,000	$561,000	+46.0%
Operating Income	-$12M	-$5M	-137.7%
Net Income	-$13M	-$5M	-148.2%